Aldeyra Therapeutics, Inc. 8-K

What Happened Aldeyra Therapeutics, Inc. filed an 8-K (Item 5.02) announcing that Chief Development Officer Stephen G. Machatha, Ph.D., notified the company on December 23, 2025 that he will voluntarily resign to pursue other opportunities. Dr. Machatha will remain employed through a Transition Period with a Separation Date on or before March 31, 2026, under a Transition Agreement to help ensure an orderly handoff of duties.

Key Details

• Transition Agreement effective December 23, 2025; Dr. Machatha will continue to receive base salary and participate in employee benefits during the Transition Period.
• Outstanding stock options and restricted stock units will continue to vest during the Transition Period per their terms.
• Aldeyra will pay Dr. Machatha a lump sum of $88,000 (50% of his potential 2025 bonus based on 110% of target) upon execution of the Transition Agreement; a second $88,000 payment is payable if he signs an additional release shortly after the Separation Date.
• The resignation was voluntary and not due to any dispute or disagreement with the company regarding operations, policies, accounting, or financial reporting; the current Offer Letter (dated Oct 21, 2015, as amended) remains in effect until separation.

Why It Matters This 8-K details an executive departure and the company’s plan to manage the transition. For investors, the filing outlines the near-term continuity measures (continued employment, vesting, and knowledge transfer) and the direct cash impact tied to the separation payments ($88k guaranteed now, $88k contingent). The disclosure that the resignation was not due to a dispute reduces potential governance or accounting concerns, while continued vesting and salary through the Transition Period indicate the company is prioritizing an orderly handover of development responsibilities.